REVIEWS   

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2010 December;54(6):654-76

Copyright © 2011 EDIZIONI MINERVA MEDICA

language: English

Targeting T and B lymphocytes with radiolabelled antibodies for diagnostic and therapeutic applications

Malviya G., Galli F., Sonni I., Pacilio M., Signore A. ✉

¹ Nuclear Medicine Unit, Second Faculty of Medicine and Surgery, La Sapienza University, Rome, Italy; ² Department of Nuclear Medicine and Molecular Imaging, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands

Acute and chronic forms of inflammation may occur years before the onset of specific symptoms, on which the clinical diagnosis can be settled, and may last for years after the clinical diagnosis and the onset of treatment. Therefore, to develop a sensitive and specific diagnostic tool several novel molecules/ receptors identified and new antibodies have been radiolabelled with different radionuclides, as per their need for diagnosis or therapy. Cluster of differentiation (CD) molecules are markers on the cell surface used to identify the cell type, stage of differentiation and activity of a cell. These CD markers are recognized by specific monoclonal antibodies (mAbs). These radiolabelled mAbs bind to their targets with high affinity and specificity and consequently have an excellent diagnostic and/ or therapeutic potential. In the last two decades, the radiolabelled mAbs have demonstrated its significant impact on diagnosis and radioimmunotherapy. In this review article, we will discuss different possible targets for T and B cells and their radiolabelled mAbs for molecular imaging and radioimmunotherapy.